| Authors | Manali Kamdar, Hongli Li, Robert W Chen, Lisa M Rimsza, Michael L Leblanc, Timothy S Fenske, Thomas C Shea, Paul M Barr, Tycel J Phillips, John P Leonard, Brad S Kahl, Jonathan W Friedberg, Sonali M Smith |
| Journal | Blood advances
(Blood Adv)
Vol. 3
Issue 20
Pg. 3132-3135
(10 22 2019)
ISSN: 2473-9537 [Electronic] United States |
| PMID | 31648328
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Rituximab
- Vincristine
- Dexamethasone
- Doxorubicin
- Cyclophosphamide
- Bendamustine Hydrochloride
|
| Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bendamustine Hydrochloride
(administration & dosage)
- Child
- Child, Preschool
- Cyclophosphamide
(adverse effects, therapeutic use)
- Dexamethasone
(adverse effects, therapeutic use)
- Doxorubicin
(adverse effects, therapeutic use)
- Female
- Humans
- Infant
- Infant, Newborn
- Kaplan-Meier Estimate
- Lymphoma, Mantle-Cell
(diagnosis, drug therapy, mortality)
- Male
- Prognosis
- Rituximab
(administration & dosage)
- Treatment Outcome
- Vincristine
(adverse effects, therapeutic use)
|
